Novo Nordisk A/S Stock Hits New 52-Week High (NVO)

NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) hit a new 52-week high Friday as it is currently trading at $152.97, above its previous 52-week high of $152.31 with 32,503 shares traded as of 9:35 a.m. ET. Average volume has been 421,800 shares over the past 30 days.

Novo Nordisk A/S has a market cap of $84.73 billion and is part of the health care sector and drugs industry. Shares are up 29.9% year to date as of the close of trading on Thursday.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 26.3 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Novo Nordisk A/S Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists